BioMérieux Buys Argene to Bolster Test Menu for Biocartis MDx Platform

In addition, Argene will provide BioMérieux with a portfolio of molecular tests for diagnosing infectious diseases in transplant and other immunocompromised patients.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.